Pfizer licensing exec
Executive Summary
Pfizer promotesVP-Worldwide Regulatory Affairs & Quality Assurance Edmund Harrigan to senior VP-worldwide licensing & business development, the company announces Oct. 13. As head of the newly created group, Harrigan will be responsible for co-promotion and licensing agreements, VC investments in new technologies and the acquisition of external products and services. The group "brings together previously separate functions so that all the capabilities and resources necessary to evaluate and secure these opportunities are in one place, with a clear strategy and accountability," Pfizer says...
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip